Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 5,221 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO William Sibold sold 5,221 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the transaction, the chief executive officer owned 197,746 shares in the company, valued at approximately $107,255,452.94. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

William John Sibold also recently made the following trade(s):

• On Wednesday, September 9th, William Sibold sold 6,362 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $535.59, for a total transaction of $3,407,423.58.

Madrigal Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:MDGL traded up $1.37 during trading hours on Friday, hitting $534.49. The company’s stock had a trading volume of 187,642 shares, compared to its average volume of 339,731. Madrigal Pharmaceuticals, Inc. has a 52 week low of $393.61 and a 52 week high of $615.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94. The company has a market capitalization of $12.35 billion, a price-to-earnings ratio of -41.47 and a beta of -0.98. The firm’s fifty day moving average price is $530.87 and its 200 day moving average price is $507.44.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.69. The firm had revenue of $364.25 million for the quarter, compared to the consensus estimate of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The company’s quarterly revenue was up 71.2% on a year-over-year basis. During the same period last year, the firm earned ($1.90) earnings per share. As a group, research analysts expect that Madrigal Pharmaceuticals, Inc. will post -7.03 EPS for the current year.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Tidal Investments LLC increased its position in shares of Madrigal Pharmaceuticals by 5.2% during the second quarter. Tidal Investments LLC now owns 1,631 shares of the biopharmaceutical company’s stock worth $876,000 after purchasing an additional 80 shares in the last quarter. Engineers Gate Manager LP acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $709,000. Arizona State Retirement System raised its stake in Madrigal Pharmaceuticals by 1.5% in the second quarter. Arizona State Retirement System now owns 4,114 shares of the biopharmaceutical company’s stock valued at $2,209,000 after buying an additional 60 shares during the last quarter. Nykredit A S purchased a new stake in Madrigal Pharmaceuticals in the second quarter valued at about $356,000. Finally, Amundi boosted its holdings in Madrigal Pharmaceuticals by 13.2% in the second quarter. Amundi now owns 1,386 shares of the biopharmaceutical company’s stock worth $744,000 after acquiring an additional 162 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 31st. Piper Sandler restated an “overweight” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, June 24th. UBS Group reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 31st. Finally, Barclays cut their target price on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Fifteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $699.64.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic diseases, particularly nonalcoholic steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH).

The company’s lead product is Rezdiffra (resmetirom), an oral, thyroid hormone receptor beta agonist designed to target underlying liver disease. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH and moderate to advanced liver fibrosis.